Development of novel small molecules for the treatment of antibiotic resistant bacterial infections (360G-Wellcome-101999_Z_13_Z)

Due to a dearth of new antibiotics in development, resistant bacteria are presenting a growing challenge to patients, physicians, and health organizations, resulting in higher patient morbidity and mortality as well as increased health system costs.For example, the alarming spread of newly emerging “CRE” (Carbapenem-Resistant Enterobacteriaceae) “super-bugs” threatens to become a global crisis. With an investment of $8.9M from the Wellcome Trust Translation Fund, VenatoRx is developing new antibacterial therapeutic products to address multi-drug resistant gram negative bacteria, including resistant E. coli, K. pneumoniae, and P. aeruginosa, important causative agents for complicated urinary tract infections, complicated intra-abdominal infections and many types of serious pneumonia.